The estimated Net Worth of Andrew Summers is at least $6.21 Millón dollars as of 14 December 2023. Andrew Summers owns over 28,797 units of Electromed stock worth over $6,207,886 and over the last 12 years Andrew sold ELMD stock worth over $0.
Andrew has made over 1 trades of the Electromed stock since 2023, according to the Form 4 filled with the SEC. Most recently Andrew bought 28,797 units of ELMD stock worth $302,369 on 14 December 2023.
The largest trade Andrew's ever made was buying 28,797 units of Electromed stock on 14 December 2023 worth over $302,369. On average, Andrew trades about 4,114 units every 0 days since 2013. As of 14 December 2023 Andrew still owns at least 351,921 units of Electromed stock.
You can see the complete history of Andrew Summers stock trades at the bottom of the page.
Andrew's mailing address filed with the SEC is 500 SIXTH AVENUE NW, , NEW PRAGUE, MN, 56071.
Over the last 14 years, insiders at Electromed have traded over $2,585,226 worth of Electromed stock and bought 684,801 units worth $2,582,707 . The most active insiders traders include Oak Partners, Llc Red, Stephen H. Craney y Kathleen Skarvan. On average, Electromed executives and independent directors trade stock every 84 days with the average trade being worth of $358,798. The most recent stock trade was executed by James L. Cunniff on 1 March 2024, trading 9,000 units of ELMD stock currently worth $137,250.
electromed, inc. is a minnesota-based company (nyse mkt: elmd) and the innovative leader in the development, manufacture, and worldwide sales of the smartvest® airway clearance system. the patented system uses high frequency chest wall oscillation (hfcwo), a better-tolerated alternative to chest physiotherapy (cpt), to deliver vigorous, yet comfortable airway clearance treatment for patients battling the consequences of retained secretions. hfcwo has been clinically proven to clear the lungs of excess mucus, improve and reduce lung infections for individuals suffering from various conditions including atelectasis, copd, bronchiectasis, neuromuscular diseases, and cystic fibrosis. electromed, inc. is accredited by the joint commission and is iso 13485:2003 and iso 9001:2008 certified.
Electromed executives and other stock owners filed with the SEC include: